Clinical Trial Update: Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer [Phase 2]

View source ↗

Summary

A phase 2 clinical trial is evaluating adding olaparib to temozolomide for advanced pheochromocytoma and paraganglioma (neuroendocrine tumors), with the study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Lynparza (olaparib)
• Temodar (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING